FDA, EU To Redouble Inspection Of Asian Pharmaceutical Supply Chains

Mutual recognition agreement enables US and European authorities to redirect inspectional resources to China and India. The result could be more warning letters and other actions unless global companies strengthen oversight of ingredient suppliers and contract manufacturers in Asia, current and former FDA officials say.

More from Compliance

More from Pink Sheet